Evidence map›Paper›PMID 38867688›Full record

ReviewJournal of the National Cancer Institute2024

Resource requirements to accelerate clinical applications of next-generation sequencing and radiomics: workshop commentary and review.

Lyndsay Harris, Lalitha K Shankar, Claire Hildebrandt, Wendy S Rubinstein, Kristofor Langlais, Henry Rodriguez, Adam Berger, John Freymann, Erich P Huang, P Mickey Williams and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lyndsay HarrisCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-9774-6719
Lalitha K ShankarCancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Claire HildebrandtCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0009-0009-8913-6337
Wendy S RubinsteinBreast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kristofor LanglaisOffice of In Vitro Diagnostics (OHT7), Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA.
Henry RodriguezOffice of Cancer Clinical Proteomics Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Adam BergerDivision of Clinical and Healthcare Research Policy, Office of Science Policy, National Institutes of Health, Bethesda, MD, USA.
John FreymannLeidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Erich P HuangBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
P Mickey WilliamsLeidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jean Claude ZenklusenThe Cancer Genome Atlas, Center for Cancer Genomics, Office of the Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Robert OchsOffice of Health Technology 8, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA.
Zivana TezakOffice of In Vitro Diagnostics (OHT7), Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA.
Berkman SahinerDivision of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The National Institutes of Health-US Food and Drug Administration Joint Leadership Council Next-Generation Sequencing and Radiomics Working Group was formed by the National Institutes of Health-Food and Drug Administration Joint Leadership Council to promote the development and validation of innovative next-generation sequencing tests, radiomic tools, and associated data analysis and interpretation enhanced by artificial intelligence and machine learning technologies. A 2-day workshop was held on September 29-30, 2021, to convene members of the scientific community to discuss how to overcome the "ground truth" gap that has frequently been acknowledged as 1 of the limiting factors impeding high-quality research, development, validation, and regulatory science in these fields. This report provides a summary of the resource gaps identified by the working group and attendees, highlights existing resources and the ways they can potentially be employed to accelerate growth in these fields, and presents opportunities to support next-generation sequencing and radiomic tool development and validation using technologies such as artificial intelligence and machine learning.

Indexed as

High-Throughput Nucleotide SequencingArtificial IntelligenceHumansMachine LearningNational Institutes of Health (U.S.)NeoplasmsRadiomicsUnited StatesUnited States Food and Drug Administration

Identifiers

PMID38867688
PMCPMC12116286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.